Fujian Provincial Key Laboratory of Tumor Biotherapy

Fuzhou, China

Fujian Provincial Key Laboratory of Tumor Biotherapy

Fuzhou, China
SEARCH FILTERS
Time filter
Source Type

Chen Y.,Fujian Medical University | Chen Y.,Fujian Provincial Key Laboratory of Tumor Biotherapy | Li L.,Fujian Medical University | Lu J.,Fujian Medical University | And 4 more authors.
International Journal of Clinical and Experimental Medicine | Year: 2017

Background: Non-Hodgkin lymphoma (NHL) involvement of the uterus is rare. Histologically, the majority of previously reported cases of NHL involving the female genital tract have been aggressive B-cell lymphomas, while natural killer (NK)/T-cell lymphoma involving the uterus is extremely rare. Case presentation: We report a case of primary cervical extranasal NK/T-cell lymphoma in a 36-year-old Chinese woman who complained of irregular vaginal bleeding. A computerized tomographic (CT) scan of the pelvis revealed a mass about 5 cm in size in the cervix with evidence of pelvic lymph node enlargement. Microscopic examinations showed prominent necrosis, angiocentric growth and diffuse infiltration by medium- to large-sized atypical lymphoid cells. The neoplastic cells were negative for CD20 and positive for cytoplasmic CD3, CD56, and granzyme B. In-situ hybridization showed that the tumor cells were positive for Epstein-Barr virus (EBV)-encoded small RNAs (EBERs). Based on these findings, the diagnosis of primary cervical extranasal natural killer (NK)/T-cell lymphoma was made. Four months after the chemotherapy and local radiation therapy, a mass lesion of the right orbit was observed by follow-up magnetic resonance imaging (MRI). In spite of intensive chemotherapy, the patient died of disease dissemination with an overall survival of 15 months. Conclusions: Due to its rarity and nonspecific clinical signs, uterine cervical lymphoma is sometimes a diagnostic challenge. The case described here may be of value in elucidating the biological behavior and natural history of NK/T-cell lymphoma. © 2017, E-Century Publishing Corporation. All rights reserved.


Chen Y.-P.,Fujian Medical University | Chen Y.-P.,Fujian Provincial Key laboratory of Tumor Biotherapy | Chen B.-Z.,Fujian Medical University | Zhu W.-F.,Fujian Medical University | And 4 more authors.
Experimental and Molecular Pathology | Year: 2017

Extranodal NK/T-cell lymphoma (ENKTL), nasal type is an aggressive lymphoma characterized by rapid clinical progression, an unfavorable prognosis, and a short survival time. This study aimed to investigate the correlations of c-MYC protein expression, gene rearrangement, and gene copy number with the prognosis of ENKTL. Immunohistochemistry for CD20, CD3, CD56, TIA-1, Ki-67, and c-MYC were performed using tissue sections from 68 patients diagnosed with ENKTL. In situ hybridization was performed to detect Epstein-Barr virus (EBV)-encoded small RNA (EBER). c-MYC genetic alterations (located on chromosome 8q24) were detected using fluorescence in situ hybridization. Sixty patients with nasopharyngeal mucosa lymphadenosis were selected as a normal control group for the c-MYC gene and protein. Immunophenotypically, CD3 and TIA-1 were positive in all patients, CD56 was positive in 54 patients (79.4%), and CD20 was negative in all patients. A Ki-67 proliferation index of > 50% was observed in 94.1% of patients (64/68). In situ hybridization for EBER was positive in all patients. The c-MYC positive expression rate (> 40% of tumor cells with nuclear staining regarded as positive) in patients with ENKTL was 50% (34/68), which was significantly higher than that in patients with nasopharyngeal mucosa lymphadenosis (0%, 0/60; p < 0.05). Treatment efficacy was poor in patients with high c-MYC protein expression (p < 0.05). Genetically, c-MYC rearrangements were not detected in any patients, but 26.5% (18/68) had increased c-MYC copy numbers. The gain of c-MYC copy numbers was positively correlated with c-MYC protein expression (p < 0.05). Kaplan-Meier analysis illustrated that overall survival was significantly shorter in the c-MYC-positive group than in the c-MYC-negative group (p < 0.05). Gain of c-MYC copy numbers was not associated with prognosis (p > 0.05). Multivariate Cox regression analysis further confirmed that clinical stage and c-MYC positivity were independent prognostic factors in patients with ENKTL. The abnormal expression of c-MYC may play an important role in the development and progression of ENKTL and influence the prognosis of patients. © 2017


Zheng Y.,Fujian Medical University | Zheng Y.,Fujian Provincial Key Laboratory of Tumor Biotherapy | Wang Z.,Fujian Medical University | Wang Z.,Fujian Provincial Key Laboratory of Tumor Biotherapy | And 3 more authors.
Oncotarget | Year: 2017

The present study aims to investigate the clinical implication of supraclavicular lymph nodes (SCLNs) in thoracic esophageal squamous cell carcinoma (ESCC). A total of 1156 ESCC patients who underwent three-field lymphadenectomy with node metastasis were analyzed retrospectively. SCLNs were defined as regional nodes in the current system or as distant nodes in the modified system. Survival was analyzed using the Kaplan-Meier method, and values were compared using the log-rank test. Multivariate analysis was performed using the Cox proportional hazard model. The Akaike information criterion (AIC) and the concordance index (c-index) were applied to compare the two prognostic systems. Among 1156 patients, 183 (15.8%) patients were diagnosed with SCLN metastasis. Higher rate of SCLN metastasis was associated with upper tumor location, metastasis involving seven or more nodes, and positive recurrent laryngeal nerve node status. The current staging system was unable to stratify overall survival well in patients with N2, N3, and M1 status using a univariate analysis. In both the current staging system and the modified version, age, gender, pathological T status, and nodal status were independent prognostic factors in a multivariate analysis. The AIC value for the modified version was smaller than that for the current staging system; the c-index value for the modified version was larger than that for the current staging system. Based on the data from our single center, SCLNs should be reclassified as regional lymph nodes in thoracic ESCC for better stratification of overall survival. © Yuzhen Zheng et al.


Wang F.,Fujian Medical University | Zheng Y.,Guangzhou University | Wang Z.,Fujian Medical University | Wang Z.,Fujian Provincial Key Laboratory of Tumor Biotherapy | And 3 more authors.
Annals of Thoracic Surgery | Year: 2017

Background: The clinical and prognostic implications of nodal skip metastasis (NSM) remain unclear in patients with esophageal squamous cell carcinoma (ESCC). Methods: Patients with pathologically confirmed node metastasis who underwent three-field lymphadenectomy from January 1999 to December 2008 were retrospectively enrolled. The node station is determined based on the classification of the Japanese Society for Esophageal Diseases. NSM is defined as the occurrence of metastases in nodes distant from the primary tumor (station 2 or 3) without the involvement of the adjacent nodes (station 1). To balance the baseline characteristics, a matched cohort was generated by propensity score matching analysis with covariates of age, sex, pathologic status, and treatment. The prognostic implication of NSM was assessed using log-rank tests and Cox regression analyses. Results: In the entire cohort, the NSM rate was 64.0% (657 of 1026); NSM was substantially associated with clinicopathologic variables, including an increased likelihood of middle thoracic tumor location and limited nodal status. Univariate analysis showed similar outcomes between patients with and without NSM (unadjusted hazard ratio [HR] 1.018, 95% confidence interval [CI]: 0.855 to 1.213, p = 0.838). A similar result was obtained in the matched cohort (unadjusted HR 1.057, 95% CI: 0.870 to 1.285, p = 0.578). Although in patients with solitary node metastasis, patients with NSM presented a worse prognosis than patients without (p = 0.043 in log-rank test). Conclusions: NSM is a common phenomenon in ESCC. Among ESCC patients who underwent three-field lymphadenectomy, NSM is associated with a relatively poor prognosis in individuals with solitary node metastasis. © 2017 The Society of Thoracic Surgeons.


Chen Y.,Fujian Medical University | Chen Y.,Fujian Key Laboratory of Translational Cancer Medicine | Tang W.-F.,Jiangsu University | Lin J.,Fujian Medical University | And 8 more authors.
International Journal of Clinical and Experimental Medicine | Year: 2015

We aim to evaluate the efficacy and safety of paclitaxel-based doublet intravenous chemotherapy (IVC) with and without intraperitoneal chemotherapy (IPC) as the first-line treatment in advanced gastric cancer (AGC) with peritoneal metastasis (PM). 173 AGC patients with peritoneal metastasis were enrolled. All patients received paclitaxel-based doublet systemic chemotherapy Among them, 117 patients received IVC+IPC and 56 patients received IVC alone. The median OS of patients in the IP+ group was longer than the IP- group, however, there was no statistical difference between the two groups (11.1 months vs. 10.1 months, P = 0.072). In the multivariate analysis, the ECOG PS and IVC±IPC were independent prognostic factors for PFS and OS. There were no significant differences in the incidence of grade 3 and 4 toxicity between the IP+(DDP), IP+(FUDR) and IP- groups. Paclitaxel-based doublet regimens combining with IPC is effective, feasible and tolerated in AGC patients with PM. © 2015, International Journal of Clinical and Experimental Medicine. All rights reserved.


Chen Y.,Fujian Medical University | Chen Y.,Fujian Key Laboratory of Translational Cancer Medicine | Lin G.,Fujian Medical University | Lin G.,Fujian Key Laboratory of Translational Cancer Medicine | And 9 more authors.
PLoS ONE | Year: 2013

Objective:To investigate the clinical significance of the expression of MHC class I chain-related gene A (MICA) in patients with advanced non-small cell lung cancer and explore the relationship between MICA expression and the efficacy of cytokine-induced killer cell (CIK) therapy for treating advanced non-small cell lung cancer.Methods:We obtained data on 222 patients with advanced non-small cell lung cancer, including data on MICA expression, age, gender, ECOG score, pathological type, stage, treatment history (including 38 patients who were given autologous CIK cell infusion), and overall survival (OS). MICA expression in lung cancer tissue was evaluated by immunohistochemical staining. Analyses of MICA expression, and CIK therapy association with survival outcomes were performed using Cox proportional models, Kaplan-Meier methods, and the log-rank test.Result:s MICA was expressed in both membrane and cytoplasm. MICA expression correlated with the stage of lung cancer, ECOG score, gender and age. Multivariate COX regression analysis showed that the expression of MICA was an independent prognostic factor of advanced non-small cell lung cancer (p = 0.002). In subgroup analysis, we divided the 222 patients into CIK and control groups. In the CIK group, the medium OS (mOS) of patients with a high expression of MICA was longer than in those with low expression of MICA (27 months vs. 13 months). In the control group, the mOS in patients with a high expression of MICA was shorter than in patients with low MICA expression (9 months vs. 18 months). COX regression analysis showed that the MICA expression affects the effect of CIK therapy (p<0.0001).Conclusion:1) The high expression of MICA is one of the indicators of a poor prognosis for advanced non-small cell lung cancer patients. 2) The high expression of MICA might be one of the predictive factors for successful CIK therapy. © 2013 Chen et al.


Chen Y.,Fujian Medical University | Wang X.-J.,Fujian Medical University | Wang X.-J.,Fujian Key Laboratory of Translational Cancer Medicine | Lin R.-B.,Fujian Medical University | And 6 more authors.
Tumori | Year: 2014

Aims and background. Peritoneal metastasis (PM) in patients with advanced gastric cancer (AGC) is a poor prognostic indicator. The aim of this study was to compare the response of AGC patients with PM to paclitaxel-based systemic multidrug chemotherapy with and without additional intraperitoneal (IP) chemotherapy through retrospective analysis.Methods and study design. Two hundred and sixty-three AGC patients with PM were enrolled. Eighty-two patients received systemic paclitaxel/oxaliplatin and leucovorin/ 5-fluorouracil (POF) and 181 patients received 2-drug systemic therapies, PO (paclitaxel + oxaliplatin) or PF (paclitaxel + 5-fluorouracil + leucovorin), and IP infusion of a third drug.Results. Patients who received the POF regimen had longer progression-free survival (PFS) and overall survival (OS) than patients who received PO/PF + IP therapy (P = 0.026 and P = 0.046), respectively. In subgroup analysis, no significant differences in PFS and OS were observed between the POF regimen and PF/PO + IP regimens in patients with isolated peritoneal metastatic disease. Patients with multiorgan metastatic disease receiving POF had better PFS and better OS than patients receiving PO/PF + IP chemotherapy (P = 0.005 and P = 0.036, respectively). In multivariate analysis, ECOG performance status and the interaction between different therapeutic strategies and multiorgan metastasis were independent prognostic factors for survival. Leukopenia, fatigue and peripheral neuropathy were higher on the triplet regimen than the doublet regimens.Conclusions. Paclitaxel-based doublet therapy combined with IP chemotherapy had more manageable toxicity and equal efficiency compared to triplet therapy for AGC patients with isolated PM. The POF regimen may be a good choice for AGC patients with multiorgan metastasis, especially those having a good performance status.


Guo Z.,Fujian Medical University | Guo Z.,Fujian Key Laboratory of Translational Cancer Medicine | Guo Z.,Fujian Provincial Key Laboratory of Tumor Biotherapy | Wang X.,Fujian Medical University | And 9 more authors.
Journal of Chemotherapy | Year: 2015

The aim of this study was to evaluate the efficacy and safety of paclitaxel-based regimens as first-line treatments in advanced gastric cancer. We reviewed 397 previously untreated patients with advanced gastric cancer, who non-randomly received one of three paclitaxel-based regimens: paclitaxel plus fluorouracil/leucovorin (PF), paclitaxel plus oxaliplatin (PO), and paclitaxel plus oxaliplatin plus fluorouracil/ leucovorin (POF) between January 2003 and December 2010. The PF, PO, and POF response rates were 47.13, 52.08, and 63.78%, respectively. Overall survivals (OS) were 11.2, 11.7, and 11.7 months, respectively. Progression-free survivals (PFS) were 6.6, 7.2, and 7.1 months, respectively. Leucopenia was higher on the triplet regimen than the doublet regimens. The paclitaxel-based regimens appeared to be effective in patients with advanced gastric cancer. The triplet regimen produced a higher response rate than either doublet regimen with more side effects, while survivals were similar among all three treatments. © 2015 Edizioni Scientifiche per l’Informazione su Farmaci e Terapia

Loading Fujian Provincial Key Laboratory of Tumor Biotherapy collaborators
Loading Fujian Provincial Key Laboratory of Tumor Biotherapy collaborators